annb0t
Top 20
Key Insights
Mayne Pharma Group's estimated fair value is AU$7.77 based on 2 Stage Free Cash Flow to Equity Mayne Pharma Group is estimated to be 49% undervalued based on current share price of AU$3.94 Our fair value estimate is 35% lower than Mayne Pharma Group's analyst price target of AU$5.06
Does the March share price for Mayne Pharma Group Limited (ASX:MYX) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and disc...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Shares Could Be 49% Below Their Intrinsic Value Estimate
Mayne Pharma Group's estimated fair value is AU$7.77 based on 2 Stage Free Cash Flow to Equity Mayne Pharma Group is estimated to be 49% undervalued based on current share price of AU$3.94 Our fair value estimate is 35% lower than Mayne Pharma Group's analyst price target of AU$5.06
Does the March share price for Mayne Pharma Group Limited (ASX:MYX) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and disc...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Shares Could Be 49% Below Their Intrinsic Value Estimate
